Cargando…

P1155: MORE PRECISE RISK STRATIFICATION FOR TP53 MUTANT DIFFUSE LARGE B CELL LYMPHOMA

Detalles Bibliográficos
Autores principales:	Du, Kai-Xin, Wu, Yi-Fan, Wu, Jia-Zhu, Shen, Haorui, Yin, Hua, LI, Yue, Wang, LI, LI, Jianyong, Liang, Jinhua, Xu, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430961/ http://dx.doi.org/10.1097/01.HS9.0000971516.04108.68

Ejemplares similares

Bortezomib depended on PRDM1 and TP53 to exert therapeutic effect in activated B-cell-like diffuse large B-cell lymphoma
por: Tang, Jing, et al.
Publicado: (2023)

Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma
por: Voropaeva, Elena N., et al.
Publicado: (2019)

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients
por: Qin, Yan, et al.
Publicado: (2020)

Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma
por: Fang, Ying, et al.
Publicado: (2023)

Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma
por: Kliebhan, Johannes, et al.
Publicado: (2022)

Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma
por: Ebid, Osama Abd El Hameed, et al.
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Porpaczy, Edit, et al.
Publicado: (2021)

PB2385: CINOBUFAGIN PROMOTES APOPTOSIS OF DIFFUSE LARGE B LYMPHOMA CELLS BY INHIBITING UBIQUITINATION DEGRADATION OF TP53
por: He, Sanxiu, et al.
Publicado: (2023)

TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia
por: Maschietto, Mariana, et al.
Publicado: (2014)

Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats
por: Li, Yanjun, et al.
Publicado: (2022)

Molecular profiling identifies distinct subtypes across TP53 mutant tumors
por: Chen, Xin, et al.
Publicado: (2022)

1155. Clinical and Epidemiological Characteristics of Patients with Paracoccidioidomycosis in Asuncion Paraguay
por: Núñez, Fátima M, et al.
Publicado: (2020)

TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP
por: Liu, Yalu, et al.
Publicado: (2017)

P1145: PRELIMINARY RESULTS OF PENPULIMAB COMBINED WITH RMA(RITUXIMAB, METHOTREXATE, AND CYTARABINE) FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Shen, Haorui, et al.
Publicado: (2023)

Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors
por: Cao, Yang, et al.
Publicado: (2016)

Regulators of Oncogenic Mutant TP53 Gain of Function
por: Yamamoto, Satomi, et al.
Publicado: (2018)

P1220: EXPLORING TP53 BIOLOGY IN DIFFUSE LARGE B-CELL LYMPHOMA: A GENOMIC AND TRANSCRIPTOMIC META-ANALYSIS
por: Uppal, Manik, et al.
Publicado: (2023)

α-KG inhibits tumor growth of diffuse large B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis
por: Cai, Yiqing, et al.
Publicado: (2023)

Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma
por: Zhang, Xuzhao, et al.
Publicado: (2022)

Accurate interpretation of p53 immunohistochemical patterns is a surrogate biomarker for TP53 alterations in large B-cell lymphoma
por: Li, Xinyi, et al.
Publicado: (2023)

A nomogram for predicting the rapid progression of diffuse large B‐cell lymphoma established by combining baseline PET/CT total metabolic tumor volume, lesion diffusion, and TP53 mutations
por: Liu, Cong, et al.
Publicado: (2023)

1155. Excessive Movement, Unnecessary Contamination: Clostridium difficile Patients in the Hospital
por: Reese, Sara, et al.
Publicado: (2018)

Leukemic phase and CSF involvement of diffuse large B‐cell lymphoma with a complex karyotype including a TP53 deletion
por: Sinkoff, Jillian, et al.
Publicado: (2017)

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP
por: Qin, Yan, et al.
Publicado: (2022)

Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another “double hit” lymphoma with very poor outcome?
por: Asmar, Fazila, et al.
Publicado: (2014)

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM
por: Wang, Y., et al.
Publicado: (2022)

The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies
por: Yang, Chang, et al.
Publicado: (2021)

Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics
por: Yang, Yang, et al.
Publicado: (2022)

Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature
por: Liu, Hua-Ping, et al.
Publicado: (2023)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

1155 Origin of the dengue virus outbreak in Martin County, Florida, USA 2013
por: Ramgopal, Moti N., et al.
Publicado: (2014)

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy
por: Wu, Chih‐Hsun, et al.
Publicado: (2019)

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
por: Lobello, Cosimo, et al.
Publicado: (2020)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

NEK2, a promising target in TP53 mutant cancer
por: Cusan, Martina, et al.
Publicado: (2022)

Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
por: Kim, Jin-Ah, et al.
Publicado: (2023)

TP53 mutation status: emerging biomarker for precision radiation medicine?
por: Willers, Henning, et al.
Publicado: (2018)

TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosis
por: Dobashi, Akito, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tqp747hg44b229ul57uk67ji8e